GLP-1 receptor agonists, a class of drugs initially developed to manage type 2 diabetes, have recently gained widespread…

This article Think GLP-1 drugs are a miracle? Wait until you hear about the hidden risks that nobody’s talking about! 😳 appeared first on Guerilla Stock Trading.

Altimmune (ALT) stock is experiencing a significant upward movement, driven by multiple factors that have garnered investor attention.…

This article Altimmune’s stock is on the rise—$20 price target, strong clinical data, could be the next big thing in the obesity drug market! 💊 appeared first on Guerilla Stock Trading.

Viking Therapeutics’ stock surged in after-hours trading on July 24, 2024, due to several positive developments. The company…

This article Viking Therapeutics is on fire! Q2 earnings beat expectations and obesity treatment advances to Phase 3! 🚀 appeared first on Guerilla Stock Trading.

Positive Clinical Trial Results Propel Altimmune Altimmune (ALT) has recently caught the attention of investors, with its stock…

This article Altimmune’s obesity drug shows jaw-dropping 15.6% weight loss – could this be the future of weight loss? 💊 appeared first on Guerilla Stock Trading.

Thermo Fisher Scientific (TMO), a leading life sciences company, is experiencing growth due to the expanding GLP-1 drug…

This article Drug approvals are skyrocketing! Why Thermo Fisher is the go-to partner for the biggest breakthroughs 💊 appeared first on Guerilla Stock Trading.

A groundbreaking new class of drugs has emerged from the laboratories of biopharma companies, promising to revolutionize the…

This article Could this new class of drugs revolutionize healthcare? How GLP-1 drugs are changing the game 🔄 appeared first on Guerilla Stock Trading.

In a bold move poised to reshape the landscape of diabetes and obesity treatment, Eli Lilly announced its…

This article Eli Lilly’s Ambitious Expansion Plan: A Game-Changer for GLP-1 Medicines appeared first on Guerilla Stock Trading.

In a groundbreaking clinical trial conducted by Novo Nordisk four years ago, a drug called semaglutide demonstrated remarkable…

This article The Obesity Drug Revolution: A New Era in Weight Loss Treatment appeared first on Guerilla Stock Trading.

Amgen’s Q1 earnings report showcased a notable 22% increase in revenue, hitting $7.4 billion, aligned with expectations, while…

This article Amgen’s Q1 2024 Earnings: $7.4B Revenue Surge! appeared first on Guerilla Stock Trading.

In the ongoing battle against obesity, pharmaceutical companies are constantly striving to develop more effective treatments. Novo Nordisk,…

This article A Breakthrough in Obesity Treatment: Novo Nordisk’s Experimental Pill Shows Promise appeared first on Guerilla Stock Trading.

This article Eli Lilly’s Strong Finish to 2023 appeared first on Guerilla Stock Trading.

This article DexCom: A Rising Star in the Diabetes Care Market appeared first on Guerilla Stock Trading.

This article Novo Nordisk’s Stellar Performance Propels ADRs to Record Highs appeared first on Guerilla Stock Trading.

This article The Potential Health-Care Sector Comeback: Biotech and Medtech in Focus appeared first on Guerilla Stock Trading.

This article Michael Yee’s Positive Outlook for the Biotechnology Sector in 2024 appeared first on Guerilla Stock Trading.

This article GSBR-1290: A Promising Oral GLP-1 Receptor Agonist in Diabetes and Obesity appeared first on Guerilla Stock Trading.